Syndax Pharmaceuticals Files 8-K

TL;DR

Syndax dropped an 8-K on 10/24/25 - check it for corporate updates.

AI Summary

Syndax Pharmaceuticals, Inc. filed an 8-K on October 24, 2025, reporting other events and financial statements. The filing details the company's corporate information, including its incorporation in Delaware and principal executive offices located at 730 Third Avenue, New York, NY.

Why It Matters

This 8-K filing provides an update on Syndax Pharmaceuticals' corporate status and events, which is important for investors to stay informed about the company's regulatory and financial reporting.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

• Syndax Pharmaceuticals, Inc. (company) — Registrant
• October 24, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 730 Third Avenue, 9th Floor, New York, NY 10017 (address) — Principal Executive Offices

FAQ

Filing Documents

• sndx-20251024.htm (8-K) — 48KB
• sndx-ex99_1.htm (EX-99.1) — 59KB
• img199102934_0.jpg (GRAPHIC) — 14KB
• 0001193125-25-250052.txt ( ) — 243KB
• sndx-20251024.xsd (EX-101.SCH) — 24KB
• sndx-20251024_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On October 24, 2025, Syndax Pharmaceuticals, Inc. (the " Company ") issued a press release announcing that the U.S. Food and Drug Administration has approved Revuforj (revumenib) for the treatment of relapsed or refractory (" R/R ") acute myeloid leukemia (" AML ") with a susceptible nucleophosmin 1 (" NPM1 ") mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. A copy of the press release is filed herewith as Exhibit 99.1. The Company held a conference call regarding the announcement on October 24, 2025. The information contained in the press release is incorporated by reference into this Current Report on Form 8-K.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains "forward-looking statements," including, but not limited to, statements regarding the Company's plans to make Revuforj commercially available for patients with R/R AML with a susceptible NPM1 mutation. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any future results, performances, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "could," "plans," "anticipates," "believes," and similar expressions intended to identify forward-looking statements. These statements reflect the Company's current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Any forward-looking statements set forth in this Current Report speak only as of the date of this Current Report. The Company does not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated October 24, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNDAX PHARMACEUTICALS, INC. Date: October 24, 2025 By: /s/ Michael A. Metzger Michael A. Metzger Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR